dpp 4 glp 1 Dipeptidyl Peptidase 4: DPP4 Dipeptidyl Peptidase (DPP)-IV Inhibitors with

Ongoing research, such as the SUMMIT trial, is presently assessing the safety and efficacy of tirzepatide in HF patients with preserved ejection fraction (HFpEF)

ITCs can inhibit angiogenesis and metastasis

Parameters used in animal studies are specific to those study designs and are not validated for human use

Long-Term Safety: Although GLP-1 medications have demonstrated efficacy and safety in clinical trials, their long-term safety profile is still being evaluated

While prior large-scale studies earlier in 2024 did not find an association between GLP-1 receptor agonists and retinopathy, this recent case series suggests that a subset of patients may be vulnerable to optic nerve damage and other vision complications [1,2]

To schedule your personal consultation at our Berkeley office, please call (510) 637-9394 or submit our online contact form